{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:49:56Z","timestamp":1762033796574,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00520-020-05977-x","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:56:38Z","timestamp":1609984598000},"page":"4269-4275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"5977_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00520-006-0176-9","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:491\u2013503","journal-title":"Support Care Cancer"},{"key":"5977_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s005200050078","volume":"5","author":"D Osoba","year":"1997","unstructured":"Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307\u2013313","journal-title":"Support Care Cancer"},{"key":"5977_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/cncr.21222","volume":"104","author":"RJ Gralla","year":"2005","unstructured":"Gralla RJ, de Wit R, Herrstedt J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5-HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864\u2013868","journal-title":"Cancer"},{"key":"5977_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","volume":"24","author":"R Chow","year":"2016","unstructured":"Chow R, Chiu L, Navari R et al (2016) Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and phase II studies: a systematic review. Support Care Cancer 24:1001\u20131008","journal-title":"Support Care Cancer"},{"key":"5977_CR5","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","volume":"28","author":"R Chow","year":"2020","unstructured":"Chow R, Valdez C, Chow N et al (2020) Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting \u2013 a systematic review and meta-analysis. Support Care Cancer 28:2095\u20132103","journal-title":"Support Care Cancer"},{"key":"5977_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JGO.2015.002477","volume":"3","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, Poudyal B, Iddawela M (2016) Cheaper options in the prevention of chemotherapy-induced nausea and vomiting. J Glob Oncol 3:145\u2013153","journal-title":"J Glob Oncol"},{"key":"5977_CR7","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00520-018-4237-7","volume":"26","author":"R Chow","year":"2016","unstructured":"Chow R, Warr DG, Navari RM et al (2016) Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer 26:2519\u20132549","journal-title":"Support Care Cancer"},{"key":"5977_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2018.02.001","volume":"124","author":"M Di Maio","year":"2018","unstructured":"Di Maio M, Baratelli C, Bironzo P et al (2018) Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 124:21\u201328","journal-title":"Crit Rev Oncol Hematol"},{"key":"5977_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21037\/jhmhp.2018.04.05","volume":"2","author":"R Chow","year":"2018","unstructured":"Chow R, Warr DG, Navari RM et al (2018) Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. J Hosp Manag Health Policy 2:25","journal-title":"J Hosp Manag Health Policy"},{"key":"5977_CR10","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"5977_CR11","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guidelines update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133","journal-title":"Ann Oncol"},{"key":"5977_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00520-014-2138-y","volume":"22","author":"CM Hocking","year":"2014","unstructured":"Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143\u20131151","journal-title":"Support Care Cancer"},{"key":"5977_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0885-3924(03)00143-X","volume":"25","author":"M Srivasta","year":"2003","unstructured":"Srivasta M, Brito-Dellan N, Davis MP et al (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25:578\u2013582","journal-title":"J Pain Symptom Manag"},{"key":"5977_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663","journal-title":"Support Care Cancer"},{"key":"5977_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"5977_CR16","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M et al (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392","journal-title":"Support Care Cancer"},{"key":"5977_CR17","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"28","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 28:3240\u20133261","journal-title":"J Clin Oncol"},{"key":"5977_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/CCO.0000000000000450","volume":"30","author":"J Herrstedt","year":"2018","unstructured":"Herrstedt J (2018) The latest consensus on antiemetics. Curr Opin Oncol 30:233\u2013239","journal-title":"Curr Opin Oncol"},{"key":"5977_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00520-018-4400-1","volume":"27","author":"S Chanthawong","year":"2019","unstructured":"Chanthawong S, Lim YH, Subongkot S et al (2019) Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. Support Care Cancer 27:1109\u20131119","journal-title":"Support Care Cancer"},{"key":"5977_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/jama.2019.13978","volume":"322","author":"W Shrank","year":"2019","unstructured":"Shrank W, Rogstad T, Parekh N (2019) Waste in the US health care system. JAMA 322:1501","journal-title":"JAMA"},{"key":"5977_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3111\/13696998.2010.547237","volume":"14","author":"C Craver","year":"2011","unstructured":"Craver C, Gayle J, Balu S et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14:87\u201398","journal-title":"J Med Econ"},{"key":"5977_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1573408015666190620165507","volume":"15","author":"EI Bahbah","year":"2019","unstructured":"Bahbah EI, Abdalla AR, Abdelshafy K et al (2019) Should olanzapine be advocated over conventional anti-emetics for the prevention of chemotherapy-induced nausea and vomiting? An updated meta-analysis of randomized control trials. Curr Enzym Inhib 15:80\u201390","journal-title":"Curr Enzym Inhib"},{"key":"5977_CR23","first-page":"37","volume":"97","author":"W Wang","year":"2018","unstructured":"Wang W, Lou G, Zhang Y (2018) Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer. Medicine 97:37","journal-title":"Medicine"},{"key":"5977_CR24","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index \u2013 Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522\u2013527","journal-title":"Support Care Cancer"},{"key":"5977_CR25","unstructured":"Olanzapine prices, coupons and patient assistance programs [Internet]. 2020 Mar 2 [cited 2020 Mar 5]. Available from: https:\/\/www.drugs.com\/price-guide\/olanzapine"},{"key":"5977_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cncr.22823","volume":"110","author":"Y Shih","year":"2007","unstructured":"Shih Y, Xu Y, Elting L (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678\u2013685","journal-title":"Cancer"},{"key":"5977_CR27","first-page":"5","volume":"e000621","author":"JG Zhou","year":"2020","unstructured":"Zhou JG, Huang L, Jin SH et al (2020) Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open e000621:5","journal-title":"ESMO Open"},{"key":"5977_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bcp.13242","volume":"83","author":"T Yang","year":"2017","unstructured":"Yang T, Liu Q, Lu M et al (2017) Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol 83:1369\u20131379","journal-title":"Br J Clin Pharmacol"},{"key":"5977_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.18549\/PharmPract.2017.01.877","volume":"15","author":"L Chelkeba","year":"2017","unstructured":"Chelkeba L, Gidey K, Mamo et al (2017) Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Pharm Pract (Grenada) 15:877","journal-title":"Pharm Pract (Grenada)"},{"key":"5977_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05977-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05977-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T03:23:14Z","timestamp":1624850594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05977-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5977"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05977-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Mr. Chow has nothing to disclose. Mr. Chiu has nothing to disclose. Dr. Herrstedt reports personal fees from SOBI, personal fees from GSK, outside the submitted work. Dr. Aapro reports personal fees and non-financial support from Multinational Association for Supportive Care in Cancer, personal fees and non-financial support from European Society of Medical Oncology, personal fees and non-financial support from European Cancer Organisation, grants and personal fees from Helsinn, personal fees from Tesaro, grants and personal fees from Sandoz, personal fees from Merck USA, personal fees from Vifor, personal fees from Pfizer, personal fees from Taiho, and personal fees from Kyowa Kirin, outside the submitted work. Dr. Lock reports consulting fees from Ferring, Abbvie, Sanofi, and AstraZeneca in the past 10 years outside the submitted work. Dr. DeAngelis has nothing to disclose. Dr. Navari has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"N\/A","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}